PMID: 7513603May 15, 1994Paper

Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy

Cancer
B A MurphyGeorge J Bosl

Abstract

Serum tumor marker regression (alpha-fetoprotein [AFP] and human chorionic gonadotrophin [hCG]) was studied in patients treated with ifosfamide-based chemotherapy for cisplatin-resistant germ cell tumors (GCT) to investigate the role of marker regression as a predictor of treatment outcome. Fifty-four patients treated with cisplatin and ifosfamide-containing therapy were the subject of this retrospective analysis. The serum tumor marker half-life (T1/2) for the first two cycles of therapy was calculated for each patient using all marker values Day 7 through the end of the second treatment cycle. A calculated T1/2 for hCG of less than or equal to 3 days or a calculated T1/2 for AFP of less than or equal to 7 days was defined as appropriate marker regression; any T1/2 greater than these values was considered prolonged. A variable designated "marker decline" was defined to indicate whether the serum tumor marker half-life of AFP and/or hCG was satisfactory or unsatisfactory for each individual patient. Both univariate and multivariate analyses were conducted to investigate "marker decline" as a predictor for response, event-free survival (time to death or relapse), and overall survival. Satisfactory marker decline predicted an imp...Continue Reading

References

Nov 18, 1992·Journal of the National Cancer Institute·R J Motzer, G J Bosl
Sep 1, 1991·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A HarstrickC Bokemeyer
Oct 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G J BoslM Bains
Jun 4, 1987·The New England Journal of Medicine·S D WilliamsP J Loehrer
Jul 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C R NicholsS N Wolff
Jul 15, 1972·American Journal of Obstetrics and Gynecology·J L VaitukaitisG T Ross
Oct 1, 1982·The Journal of Urology·P H LangeE E Fraley

❮ Previous
Next ❯

Citations

Dec 22, 1999·International Journal of Cancer. Journal International Du Cancer·M J Morris, G J Bosl
May 2, 2012·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·Ibrahim QaddoumiAmar Gajjar
Apr 1, 1996·Critical Reviews in Oncology/hematology·S CulineJ P Droz
Aug 30, 2005·European Urology·Peter AlbersGiorgio Pizzocaro
Dec 1, 1996·American Journal of Clinical Oncology·B J KennedyE E Fraley
Apr 16, 1998·International Journal of Urology : Official Journal of the Japanese Urological Association·K KoshidaM Namiki
Dec 21, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R AlmuftiB You
Sep 23, 2014·Expert Opinion on Biological Therapy·Andrea NecchiUNKNOWN European Society for Blood and Marrow Transplantation, Solid Tumors Working Party (EBMT-STWP) and the Italian Germ Cell Canc
Dec 23, 2011·Actas urologicas españolas·P AlbersUNKNOWN European Association of Urology
Jun 3, 2011·European Urology·Peter AlbersUNKNOWN European Association of Urology
Sep 5, 1998·The Urologic Clinics of North America·P M DoddD F Bajorin
May 9, 2007·The Urologic Clinics of North America·Guy C Toner
Oct 14, 2014·Urologic Oncology·Brent O'Carrigan, Peter Grimison
Jan 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David J Vaughn, Edward A Stadtmauer
Apr 13, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sven-Erik OlofssonEva Cavallin-Ståhl
Aug 21, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H J SchmollUNKNOWN European Germ Cell Cancer Consensus Group
May 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M MazumdarG J Bosl
Dec 24, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Adriana FonsecaFurqan Shaikh

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.